Stockholm —31 January, 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 4,750,000 shares, which was carried out in January 2019
The share issue entails a dilution of approximately 10 percent of the number of shares and votes in the company. Through the issue, the number of outstanding shares and votes will increase by 4,750,000 from 44,091,921 to 48,841,921. The share capital will increase by approximately SEK 527,778 from SEK 4,899,102 to SEK 5,426,880.
For more information, please contact:
Jakob Lindberg, CEO of Oncopeptides
Cell phone: +46 8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 70 853 72 92
This is information that Oncopeptides AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 14:00 CET on 31 January.
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
More information is available on www.oncopeptides.com.